Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Oral presentation

Overview of osteoimmunology: What's happened? And what's going on?

Author: Hiroshi Takayanagi

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

The interaction between the immune and skeletal systems has long been acknowledged, but molecular mechanisms linking the two systems have not been demonstrated until recently. Investigation into autoimmune arthritis as well as the various bone phenotypes found in mice deficient in immunomodulatory molecules has highlighted the importance of the dynamic interplay between the two systems and brought about a rapid evolution of the field of osteoimmunology [1]. In bone loss in autoimmune arthritis, IL-17-producing helper T (TH17) cells play a major role by inducing RANKL [2]. Maintenance and mobilization of hematopoietic cells are regulated by bone cells. In addition to cellular interactions via cytokines, the immune and skeletal systems share various molecules, including transcription factors, signaling molecules and membrane receptors. RANKL stimulates osteoclastogenesis through NFATc1 in cooperation with immunoglobulin-like receptors. Here I will discuss emerging topics in osteoimmunology including the mechanisms underlying bone cell communication: osteocyte RANKL [3] and inhibition of bone formation by osteoclast Sema4D [4]. …
Literature
Metadata
Title
Overview of osteoimmunology: What's happened? And what's going on?
Author
Hiroshi Takayanagi
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3567

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine